Searching of a Different Approach for Target Therapy of Papillary Thyroid Cancer

GM Artykbaeva* and NA Alimjanov

1Institute of Bioorganic Chemistry Academy of Sciences, Uzbekistan
2The Center for the Scientific and Clinical Study of Endocrinology, Ministry of Health, Uzbekistan

*Corresponding author: GM Artykbaeva, Institute of Bioorganic Chemistry Academy of Sciences, Tashkent, Uzbekistan

Submission: December 16, 2017; Published: March 21, 2018

Abstract

Among thyroid cancer papillary thyroid carcinoma is the most widely met. As it was noted below papillary carcinoma covered 90 per cent of incidents of differentiated thyroid cancer. The loss of thyroid-specific functions during tumor progression determines the resistance of thyroid tumors to traditional radiodiode therapy. Specific drugs for aggressive and metastatic thyroid cancer are required for the development of effective therapy. Tyrosine kinase inhibitors (TKIs) are emerging as new tool for aggressive thyroid cancer. Over expression of MET (mesenchymal epithelial transition) receptor is found in papillary thyroid carcinoma. We aimed to study the phosphorylation of MET in the tissue of papillary thyroid carcinoma and effect of a TKI genistein on this process. The thyroid homogenates were incubated with genistein (Sigma-Aldrich, Germany) and then the phosphorylated MET was determined by Phospho-MET ELISA Kit (Sigma-Aldrich, Germany). In our studies, genistein at the concentrations of 10 and 20μM reduced receptor phosphorylation by 25.1% and 18.3%, respectively. The native serum of the patient with papillary carcinoma increased phosphorylation of MET by 44.6%. Our results provide data that genistein suppresses phosphorylation of MET in tissue of thyroid cancer in physiological doses. The effect of genistein on MET receptor, responsible for mesenchymal-epithelial transition, indicates its anti-metastatic properties.

Keywords: Thyroid Carcinoma, Tyrosine Kinase, MET Receptor, Phosphorylation, Genistein.

Abbreviations

TKIs: Tyrosine Kinase Inhibitors; MET: Mesenchymal Epithelial Transition; HGF: Hepatocyte Growth Factor; DTC: Differentiated Thyroid Carcinoma; PTC: Papillary Thyroid Cancer; FTC: Follicular Thyroid

Introduction

Differentiated thyroid carcinomas (DTCs) that arise from follicular cells are separated into two types-papillary thyroid cancer (PTC) (90%) and follicular thyroid cancer (FTC) (10%). Complete total thyroidectomy is the treatment of choice for PTC and FTC. Radioiodine is routinely recommended in high-risk patients and considered in intermediate risk DTC patients. Thyroid cancer cells may lose their iodide uptake ability and become resistant to radioiodine. The lack of specific medicines for aggressive and metastatic DTC has leads to the needs for the development of new drugs [1].

Tyrosine kinase inhibitors (TKIs) are small organic molecules inhibiting tyrosine kinase auto-phosphorylation; most of them are multi-kinase inhibitors. TKIs act on the molecular pathways involved in growth, angiogenesis, local, and distant spread of TC. TKIs are emerging as new therapies of aggressive TC, being capable of inducing clinical responses and stabilization of disease. New efforts are made to find new more effective and safe compounds and to personalize therapy in each thyroid cancer patient [2].

Overexpression of MET (mesenchymal epithelial transition) receptor is found in papillary thyroid carcinoma. Abnormal activation of MET is responsible for obtaining a tumorigenic phenotype with metastases. Activated by the growth factor of hepatocytes (HGF), MET receptor can be used as a therapeutic target for the treatment of cancer and metastases [3]. We aimed to study the phosphorylation of MET in the tissue of papillary thyroid carcinoma and effect of TKI genistein on this process. So far therapy with thyroid cancer targeted drugs remained outside the field of view of researchers due to the lack of drugs with recorded indications for thyroid cancer.

Materials and Methods

From the group of patients with various thyroid cancers, 8 tissue samples of female patients of the Center for the Scientific and Clinical Study of Endocrinology, Ministry of Health, Uzbekistan with a verified histological diagnosis of PTC at the age of 35 to 56years were selected. The median tumor diameter of papillary carcinomas was 2.5cm. The tissues of PTC were homogenized in a 0.25M
sucrese buffer-0.001M EDTA pH 7.3 and then were incubated with
genistein (Sigma -Aldrich, Germany) at the concentrations of 10
and 20μM for 1hour at 37 °C in presence of HGF (30ng/ml). The
phosphorylated MET level was determined by Phospho-MET ELISA
Kit (Sigma-Aldrich, Germany).

**Statistical Analysis**

All data were processed by Microsoft Excel, STATISTICA 6,
and Biostat programs. Intergroup differences were considered
significant at P<0.05.

**Results**

We have determined the phosphorylation of MET receptor in
the tissue of thyroid cancer. Tissue homogenates were incubated
with genistein at the concentrations of 10 and 20μM, and then the
receptor phosphorylation was measured. As a positive control, the
thyroid tissues were stimulated by blood serum of a patient with
papillary thyroid carcinoma, which is characterized by increased
amounts of growth factors, in particular, HGF. Another positive
control used was exogenous HGF (Sigma, Germany). In our
studies, genistein at the concentration of 10μM reduced receptor
phosphorylation by 25.1% (P<0.05). An increase of concentration
of genistein twice (20μM) decreased phosphorylation by 18.3%
(P<0.05). The serum of the patient with papillary carcinoma
increased phosphorylation by 44.6% (Figure 1). The specific
ligand of MET receptor-hepatocyte growth factor-also increased
phosphorylation by 64.6% (P<0.05). The serum of the patient with
papillary thyroid carcinoma, which is characterized by increased
defects of growth factors, in particular, HGF. Another positive
control used was exogenous HGF (Sigma, Germany). In our
studies, genistein at the concentration of 10μM reduced receptor
phosphorylation by 25.1% (P<0.05). An increase of concentration
of genistein twice (20μM) decreased phosphorylation by 18.3%
(P<0.05). The serum of the patient with papillary carcinoma
increased phosphorylation by 44.6% (Figure 1). The specific
ligand of MET receptor-hepatocyte growth factor-also increased
phosphorylation of the receptor by 64.6%. Our results provide
data that genistein suppresses phosphorylation of MET in tissue of
thyroid cancer in physiological doses.

**Discussion**

For PTC, over expression of the tyrosine kinase receptor
MET is characteristic, which is caused by increased secretion of
growth factor HGF [4]. HGF is a potent mitogen for epithelial
cells, follicular and C-cells of thyroid gland, promotes invasive
growth of tumors. HGF and MET are involved in the regulation
of cell migration. HGF and MET both are involved in postnatal
physiological and patho-physiological processes. Their increased
expression is found in some damaged tissues [5]. The disruption
of the pathway of MET and its ligand serves as a signal of malignancy
in humans. A large number of studies have shown that HGF and MET
are often expressed in carcinomas and other solid tumors, their
metastases, which correlates with a poor prognosis. Expression of
MET oncogene is associated with aggressive biological behavior of
the tumor and a high risk of metastasis [6,7].

In normal thyroid cells, MET is not expressed, or is expressed
at a very low level. In contrast, a high level of expression of this
oncogene is more often a molecular abnormality in papillary
thyroid cancer, including microadenomas. This indicates that
the expression of MET is a frequent and early event in the
carcinogenesis of the papillary thyroid cancer [8]. Activation of
the receptor starts with the phosphorylation of the tyrosine kinase
domain. The phosphorylated receptor triggers the underlying
mitogen-activating cascade to generate a tumorigenic signal. A
promising approach in the treatment of tumors is the blocking of
this process by various agents. For this purpose, small molecular
tyrosine kinase inhibitors are used that have the ability to bind
to the adenosine triphosphate site of the receptor and interrupt
transmission of the pathological signal. As a small molecular
inhibitor, we used isoflavone genistein. Genistein exhibits affinity
to the ATP-binding center of protein kinase by ATP-competitive
manner and serves as a potent inhibitor of tyrosine kinase activity
of growth factor receptors of transformed target cells [9]. It was
shown previously that genistein inhibited tyrosine kinase activity
only at the upper limit of the physiological dose (≥10μM) [10,11].
The role of isoflavones has traditionally been associated with
inhibition of proliferation and induction of apoptosis. Some works
provide evidence that isoflavones are involved in cellular processes
associated with tumorogenesis [12]. The effect of genistein on the
MET receptor, responsible for mesenchymal-epithelial transition,
indicates its anti-metastatic properties.

Further, overexpression of MET found in papillary carcinoma
is associated with wild type of receptor and considered to be
ligand-dependent since neither MET mutations nor the major
structural changes in the MET protein in papillary carcinoma have
been found [13]. We found no mutation in 19-21exons of MET
responsible for tyrosine kinase domain [14]. Given the role of
MET in the progression of cancer, in selecting a treatment strategy
it is important to keep in mind the mechanism of this activation.
In ligand-dependent activation, the search for ligands inhibiting
tyrosine kinase receptors is relevant. Conversely, tyrosine kinase
inhibitors will be ineffective if the protein is mutant and in the
state of constant activity. Thus, for the receptors carrying specific
mutations, expensive antibodies are efficiently synthesized. For
wild type receptors TKIs would be appropriate for use.

**Conclusion**

We have studied in vitro inhibition of the initial stage of
tumorigenic process in the postoperative tissue of thyroid cancer with a small molecular inhibitor of plant origin. Studies on this matter have been conducted on cell culture lines. In our study genistein reduced phosphorylation of MET in tissue of thyroid cancer in physiological doses. For MET associated with wild type receptor it is relevant to use small molecule inhibitors of kinase domain.

References